GO
Loading...

Bristol-Myers Squibb Co

More

  • Early Glance: Pharmaceuticals companies Monday, 6 Apr 2015 | 11:23 AM ET

    Baxter International Inc. fell$. 01 or percent, to $67.99. Bristol-Myers Squibb Co. fell$. 11 or. 2 percent, to $63.12. Eli Lilly& Co. fell$. 33 or. 5 percent, to $70.91.

  • *Herbalife shares fall after investigation report. NEW YORK, April 6- U.S. stocks edged up on Monday as expectations the Federal Reserve will push any interest rate increases further into the year offset concerns over faltering economic growth spurred by a surprisingly weak jobs report on Friday. "The market seems to be very confused whether bad or good news is...

  • *Herbalife shares fall after investigation report. NEW YORK, April 6- U.S. stock index futures fell in low volume on Monday, putting Wall Street on track for a lower open on the first trading session since Friday's surprisingly weak jobs data. *The jobs data was released on Good Friday, when Wall Street was closed.

  • FRANKFURT, April 1- Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive said. Roche is vying with rivals such as Bristol-Myers Squibb, Merck& Co and AstraZeneca to develop such immuno-oncology therapies that harness the power of the body's immune...

  • Hottest dividend stocks of 2015 Tuesday, 24 Mar 2015 | 2:58 PM ET
    A trader works on the floor of the New York Stock Exchange.

    CNBC screened the large cap S&P 500 index to see where the hottest parts of the dividend stock market have been.

  • March 24- Merck& Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease. The medicine, a PD-1 inhibitor that works by taking the brakes off the...

  • March 24- Bristol-Myers Squibb said on Tuesday it had agreed to acquire rights to a Novo Nordisk immune system research program, which the Danish company is divesting as it focuses further on diabetes care. The project aims to modulate the innate immune system as a therapy for autoimmune diseases and the U.S. drugmaker said it fitted with its long-standing...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • March 17- Foreign exchange swings cost North American corporates $18.66 billion in revenue in the fourth quarter, according to a report by currency risk management consulting firm FiREapps. A slew of U.S. multinational companies, from DuPont to Procter& Gamble, have showed that a strong U.S. dollar hurt their earnings, and several blue-chip exporters said the...

  • LONDON, March 14- Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday. The finding may boost sales of the blood-thinner, which AstraZeneca is relying on to drive growth, although doctors must balance its...

  • Nikkei edges up, BOJ's ETF buying helps sentiment Wednesday, 4 Mar 2015 | 9:28 PM ET

    *Rakuten falls after Goldman cuts rating. TOKYO, March 5- Japan's Nikkei share average edged up on Thursday after the central bank bought more exchange-traded funds, but gains were limited by investor caution ahead of U.S. jobs data on Friday. Ono Pharmaceutical Co, which co-develops cancer treatment drug Opdivo with Bristol Myers Squibb, jumped 8 percent after...

  • Cramer: As the smoke clears, these stocks win big Wednesday, 4 Mar 2015 | 6:11 PM ET
    Wall Street

    The market was hit yet again, but Jim Cramer is ready to do some buying Thursday for these stocks.

  • *Markit, ISM services show modest growth. *Healthcare stocks rise after Supreme Court oral argument. The market had a terrific February, "said David Katz, chief investment officer at Matrix Asset Advisors, in New York.

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • COPENHAGEN, March 4- Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful. The jump added over $260 million to its market value of $880 million. In that trial, patients were treated with Prostvac in addition to escalating doses of...

  • COPENHAGEN, March 4- Shares in Bavarian Nordic leapt as much as 39 percent on Wednesday after the Danish biotech company announced a prostate cancer drug deal with Bristol-Myers Squibb that could be worth at least $1 billion. Under the deal, Bavarian Nordic could receive up to $975 million, including $60 million upfront, if it passes trials and sales milestones,...

  • Feb 24- An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute. Patients were treated with the company's Prostvac vaccine, in addition to escalating doses of...

  • Cramer: Greece situation unlike the old days Tuesday, 17 Feb 2015 | 10:42 AM ET
    A protester takes part in an anti-austerity pro-government demonstration in Athens February 16, 2015.

    "This is not like the old days," CNBC's Jim Cramer says about the Greek-EU standoff.

  • Cramer Remix: What this oil price means for you Monday, 9 Feb 2015 | 7:03 PM ET
    Jim Cramer on the set of Mad Money

    Too hot? Too cold? Or has oil gone all Goldilocks on us? "Mad Money" host Jim Cramer explains the story.